Quadrivalent inactivated influenza vaccine (VaxigripTetra™)

@article{GressetBourgeois2018QuadrivalentII,
  title={Quadrivalent inactivated influenza vaccine (VaxigripTetra™)},
  author={Viviane Gresset-Bourgeois and P. S. Leventhal and St{\'e}phanie P{\'e}pin and R. Hollingsworth and Marie-Pierre Kazek-Duret and I. D. de Bruijn and S. Samson},
  journal={Expert Review of Vaccines},
  year={2018},
  volume={17},
  pages={1 - 11}
}
ABSTRACT Introduction: VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®). Areas covered: This literature review summarizes the rationale for developing quadrivalent influenza vaccines and discusses the phase III clinical trial results supporting the immunogenicity, safety, and tolerability of IIV4… Expand
15 Citations
...
1
2
...

References

SHOWING 1-10 OF 75 REFERENCES
Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study
  • 13
Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America
  • 12
...
1
2
3
4
5
...